<DOC>
	<DOCNO>NCT01165229</DOCNO>
	<brief_summary>The purpose observer-blind study evaluate efficacy , safety immunogenicity GSK Biologicals ' candidate Herpes Zoster ( HZ ) vaccine adult age â‰¥ 70 year . Two study ( Zoster-006 [ NCT01165177 ] Zoster-022 [ NCT01165229 ] ) conduct concurrently evaluate efficacy GSK1437173A vaccine . A pooled analysis data study combine conducted contingent study achieve objective . This protocol post also deal outcome measure relate pooled analysis .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster ( HZ ) Vaccine GSK1437173A Adults Aged 70 Years Older</brief_title>
	<detailed_description>This protocol summary update follow Protocol Amendment 4 change study objectives endpoint . Pooled analyse ZOSTER-006 ( NCT01165177 ) ZOSTER-022 ( NCT01165229 ) conduct primary objective herpes zoster vaccine efficacy ( HZ VE ) demonstrate ZOSTER-006 ( NCT01165177 ) ZOSTER-022 ( NCT01165229 ) separately .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . A male female age 70 year old time first vaccination . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Any confirm suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy History HZ . Previous vaccination varicella HZ . History allergic disease reaction likely exacerbate component vaccine . Additionally , consider allergic reaction material equipment relate study participation . Significant underlying illness opinion investigator would expect prevent completion study . Receipt immunoglobulins and/or blood product within 90 day precede first dose study vaccine plan administration study period . Administration plan administration immunization within 30 day first second study vaccination schedule within 30 day study vaccination . However , license nonreplicating vaccine may administer 8 day prior dose and/or least 14 day dose study vaccine . Any condition , opinion investigator , might interfere evaluation require study . Acute disease and/or fever time enrolment . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Subjects 70 year old</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>Safety</keyword>
	<keyword>Adults</keyword>
	<keyword>Vaccine</keyword>
</DOC>